MEDEZE Showcases First-Half 2025 Performance and Advances the ‘Sandbox’ Initiative to Develop Next-Generation Therapeutic Products.”
Ms. Anchisa Lekpetch (right), Chief Accounting and Finance Officer, and Dr. Wasawat Sroithong (left), Investor Relations Officer of Medeze Group Public Company Limited (MEDEZE), jointly presented the company’s second quarter 2025 performance and growth outlook at the Opportunity Day event organized by the Stock Exchange of Thailand.
For the first half of 2025, the company reported total revenue of THB 408 million, with a gross profit margin of 76% and a net profit margin of 32%, underscoring the strength of its business and the confidence it has earned from customers. The presentation also reaffirmed MEDEZE’s core strategy in driving forward the Advanced Therapy Medicinal Products (ATMPs) Sandbox, a public–private collaboration aimed at researching and developing advanced therapeutic products to support precision preventive medicine across five major disease groups.
In addition, the company has expanded its sales and marketing teams to further broaden its customer base and enhance service accessibility. Looking ahead, MEDEZE is investing in key infrastructure projects, including a new sales and marketing office building, a new warehouse facility, and a solar power system, all designed to support its long-term business expansion and reinforce its commitment to sustainable growth.
IR Press Releases